Update on Liberation Bioindustries

Summary by AI BETAClose X

Agronomics Limited has announced an update on its portfolio company, Liberation Bioindustries, which is facing a funding gap of approximately $25 million to complete its facility. Despite a strategic review and negotiations for a sale or joint venture of the Richmond facility, no acceptable offers were received, and Liberation will proceed independently. Delays and increased costs have pushed the facility completion target beyond Q4 2026, with first production now anticipated six months after securing the additional funding, expected in H1 2027. To date, Liberation has deployed $125 million in equity and debt for construction. The company's investment in Liberation, valued at £35.28 million as of June 30, 2026, representing 25% of Agronomics' £140 million net asset value, is not currently expected to be materially impacted by these delays.

Disclaimer*

UK 100

Latest directors dealings